Drug intelligence / Profile preview

caffeine + efavirenz + losartan + omeprazole + metoprolol + chlorzoxazone + midazolam

Development stage
Unknown
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Oral, Intravenous (midazolam), Other Routes Possible For Midazolam Depending On Formulation
01

Overview

This is a **combination of seven drugs**, none of which are known to be co-formulated under a unique brand or generic name. Each active ingredient is a well-established pharmaceutical agent with different mechanisms of action, primarily used individually: - **Caffeine**: a central nervous system stimulant. - **Efavirenz**: a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as an antiretroviral for HIV infection. - **Losartan**: an angiotensin II receptor blocker (ARB) used for hypertension and cardiovascular risks. - **Omeprazole**: a proton pump inhibitor (PPI) for gastric acid-related disorders. - **Metoprolol**: a beta-1 selective adrenergic receptor blocker for hypertension, angina, and heart failure. - **Chlorzoxazone**: a centrally acting muscle relaxant used for acute musculoskeletal pain and spasm[1][2][3][4][5][6][7]. - **Midazolam**: a benzodiazepine used for sedation, anesthesia, and seizure control. These seven drugs exert effects on diverse biological targets and are typically not used together outside of drug-drug interaction studies or specialized clinical protocols due to complex interactions and contraindications.

02

Targets

Human immunodeficiency virus type 1 reverse transcriptaseAGTR1 (Angiotensin II Type-1 receptor)ADOR (Adenosine receptors)

Beyond the preview

Go deeper on caffeine + efavirenz + losartan + omeprazole + metoprolol + chlorzoxazone + midazolam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on caffeine + efavirenz + losartan + omeprazole + metoprolol + chlorzoxazone + midazolam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call